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Abstract
Sleep disorders in Parkinson’s disease (PD) are common. They can develop due to many 
factors. PD symptoms like rigidity or tremor, some PD medications, restless legs syn-
drome, depression, nocturia, and degenerative changes in the brainstem can cause sleep 
disorders in PD. Sleep disorders in PD may occur during the day or at night. Sleep 
disorders can occur before or during the disease. Sleep disorders can impair patients’ 
quality of life and worsen their symptoms. For this reason, it is very important to rec-
ognize these disorders and treat them appropriately. This chapter discusses the clinical 
features, diagnosis, comorbidities, management, and pathogenesis of sleep disorders in 
PD under the literature light. At the same time, it describes the most appropriate treat-
ment considerations.
Keywords: Parkinson’s disease, sleep disorders, rapid eye movement (REM), sleep 
behavior disorder, insomnia, daytime sleepiness
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disease characterized clinically by brady-
kinesia, resting tremor, postural instability, and rigidity [1]. Parkinson’s disease is not only 
associated with motor symptoms but also with many non-motor symptoms such as sleep 
disorders, autonomic disorders, olfactory disorders, and psychiatric symptoms [2]. The spec-
trum of sleep disorders in PD is broad. In PD, the most common sleep disorders include 
insomnia [difficulty initiating sleep and its associated restless legs syndrome (RLS), as a rea-
son for the difficulty of falling into sleep, sleep fragmentation, or early awakening], excessive 
daytime sleepiness (EDS), and rapid eye movement sleep behavior disorder (RBD) [2–4]. 
While most sleep disorders occur in the advanced stages of the disease, RBD and EDS can be 
observed in the early phase and even in the premotor phase [5]. A study reported that RBD 
occurred in the premotor phase of the disease in 38% of 29 patients with PD [5]. On the other 
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hand, it has been reported that only one in four patients with PD develops RBD before the 
disease [6]. Sleep disorders, which affect more than half of the PD patients, can significantly 
affect the quality of life [7]. It has been reported that the prevalence of sleep disorders in 
patients with PD is 2–3.5 times higher than in healthy controls [6]. In the pathogenesis of 
sleep disorders in PD, many etiological factors affecting mainly the sleep-related structures 
play a role [3, 7]. In addition, in the PD, secondary factors that can negatively affect sleep 
include pharmacological agents (e.g., selective serotonin reuptake inhibitors-SSRI, serotonin-
norepinephrine reuptake inhibitors (SNRI)), nocturnal motor symptoms (e.g., akinesia and 
dystonia), nocturia, depression, cognitive impairment, and pain [3, 7, 8]. Each of the sleep 
disorders in PD can be seen individually or more than one sleep disorder can be seen in 
the same patient at the same time [3]. A recent meta-analytic study found that there was a 
significant overlap of various sleep-related symptoms in the patients with PD [3]. The study 
reported that the coexisting prevalence of two out of three sleep-related symptoms (EDS, 
PD-related sleep problems and RBD) was approximately 20%. The coexistence of all these 
three symptoms is 12.2% [3].
In this chapter, sleep disorders in patients with PD were classified, and their clinical features, 
pathophysiology, diagnostic assessment, and management were reviewed. First, a diagnosis 
of each sleep disorder was given separately, and at the end of the chapter, a general assess-
ment of sleep disorders in the PD was given. In addition, the deep brain stimulation (DBS) in 
the treatment of sleep disorders in PD was processed at the end of the chapter. This chapter 
only addresses sleep disorders related to PD.
2. Classification of sleep disorders in Parkinson’s disease
Sleep disorders in PD may occur during the day or at night. In PD, sleep disorders can be clas-
sified into three major categories such as abnormal behaviors and events during or around 
sleep (e.g., RBD), inability to sleep (e.g., insomnia), and EDS (Table 1) [6, 8]. These three cat-
egories of sleep disorders can be seen separately or together [6].
Categories Sleep disorders
Parasomnia REM parasomnias (e.g., RBD)
NREM parasomnias (e.g., sleepwalking, confusional arousals, and sleep terrors)
Inability to sleep/sleeping difficulty İnsomnia
• Initial insomnia (i.e., difficulties initiating sleep)
• Maintenance insomnia (i.e., sleep fragmentation)
• Terminal insomnia(i.e., early awakening)
Sleepiness EDS
REM: rapid eye movement; RBD: rapid eye movement sleep behavior disorder; NREM: Non-rapid eye movement; EDS: 
excessive daytime sleepiness.
Table 1. Classification of sleep disorders in Parkinson’s disease.
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3. Parasomnias in Parkinson’s disease
In PD, parasomnias are quite common, and REM parasomnias are more common than those 
in NREM [6]. As REM parasomnia in PD, RBD can be seen in near two-thirds of patients [9]. In 
PD, non-NREM (NREM) parasomnias can include sleepwalking, confusional arousals, and sleep 
terrors. However, NREM parasomnias are not a frequent cause of sleep disorders in PD [6].
4. Rapid eye movement sleep behavior disorder
4.1. Clinical features of RBD
Rapid eye movement sleep behavior disorder is a parasomnia characterized by dream-related 
vocalizations such as screaming, talking, and shouting and/or complex motor movements 
such as kicking, and punching with episodic loss of atonia during REM sleep [10, 11]. In 
severe cases, patients may be able to jump out of bed and injure themselves [6]. It has been 
reported that the prevalence of RBD in PD patients varies from 20 to 72% [9]. However, the 
most recent meta-analysis revealed that the overall prevalence of RBD symptoms in PD was 
23.6% compared to 3.4% in control [12]. In PD, the frequency of RBD in the stages of the dis-
ease is reported differently in studies. Although, in PD, RBD is a sleep disorder that can be 
seen before the disease, it can also occur at the same time or after the disease in the majority 
of patients [6]. It has been reported that RBD is associated with some specific features such as 
age, gender, motor sub types, cognition, disease duration, disease severity, antiparkinsonian 
medication, and autonomic dysfunction in PD patients [9]. It has been known that some of the 
abovementioned features such as cognitive and autonomic dysfunction in PD patients with 
RBD are more common than those without RBD. In our study, 57.6% of patients with PD had 
a clinical RBD diagnosis [13]. The frequency of clinical RBD was unrelated to motor subtypes 
of PD [13]. However, we found a weak correlation between clinical severity (i.e., the unified 
Parkinson’s disease rating scale-UPDRS and Hoehn–Yahr-HY stage scores) of PD and severity 
of clinical RBD in the non-tremor dominant-NTD subtype but not in the tremor dominant-TD 
subtype. In our study, RBD symptoms appeared before motor symptoms in approximately 
one-third of PD patients with RBD [13].
4.2. Diagnosis of RBD in PD
The diagnosis of RBD can be based on a questionnaire or clinical manifestations without 
confirmation by polysomnography (PSG) [2, 13, 14].Therefore, a detailed history of complex 
motor behaviors and vocalizations during REM sleep is very important for a clinical diagno-
sis of RBD. However, for the objective diagnosis of RBD, complex motor behaviors during 
REM sleep and the presence of REM sleep without atonia should be confirmed by PSG [11]. 
Additionally, this sleep disturbance should not be better explained by another disorder [11]. 
PSG can detect increased chin muscle tone (i.e., absence of atonia) by the submental EMG or 
increased phasic muscle activity by the limb EMG during REM sleep [2, 15]. Thus, PSG is not 
required for the clinical diagnosis of RBD [13, 14]. It has been reported that a total score of 6 or 
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higher obtained from ‘the RBD screening questionnaire (RBDSQ)’ used for the clinical diag-
nosis of RBD may strongly support (sensitivity = 0.842, specificity = 0.962) the diagnosis [16].
4.3. Pathophysiology of RBD in PD
REM sleep is regulated by the brain stem, hypothalamus, thalamus, substantia nigra, basal 
forebrain, and frontal cortex [17]. The brain stem structures involved in REM sleep include 
the pedunculopontine nucleus (PPN), retro-rubral nucleus, subcoeruleus/sublateral dorsal 
nucleus, and medullary magnocellular reticular formation (MRF) [17]. These brain stem struc-
tures provide REM atonia by inhibiting the spinal motor neurons through direct and indirect 
pathways (the reticular formation as an intermediate station inhibiting the spinal motor neu-
rons) [4, 18, 19]. Thus, these two inhibitory pathways play a role in skeletal muscle atonia dur-
ing REM sleep [4, 18, 19]. The PPN and the retro-rubral nucleus also act as a phasic generator 
circuitry [18]. It is well known that the PPN/laterodorsal tegmental nuclei (LDN) have both 
cholinergic activity and non-cholinergic (e.g., GABAergic) activity. So the PPN/LDN also con-
tains glutamatergic and GABAergic neurons [20]. On the other hand, the cholinergic neurons 
in the PPN/LDN innervate the pontine reticular formation (PRF), MRF, and thalamus [19, 
20]. Thus, descending projections of the PPN stimulate the inhibitory interneurons via the 
reticulospinal neurons and inhibit directly the motor neurons in the spinal cord and modulate 
the activations of the mesencephalic locomotor region (Figure 1) [4, 19, 21, 22]. It has been 
reported that inhibition of GABA activity in the PPN, an important part of locomotion, results 
in explosive motor behavior [23]. In addition, the ascending projections to the thalamus from 
the PPN modulate the sleep–wake cycle. It has been reported that RBD emerges as a result of 
the involvement of the atonia system and locomotor regions [4, 24]. Experimental studies sug-
gest that the locomotor regions are activated during the REM sleep and suppress locomotor 
activity [24]. Thus, neuronal dysfunction in RBD is mainly in the PPN/LDN and the sublat-
erodorsal nucleus (SLD)/pre-coeruleus (REM-on areas) directly and indirectly inhibiting the 
spinal motor neurons (Figure 1) [2, 19, 20, 23]. Finally, the PPN/LTD produces both skeletal 
muscle atonia (together with SLD) and decreased locomotion during REM sleep [4, 19]. As a 
result, by the degeneration of these neuronal structures involved in the control of REM atonia 
in RBD in PD, the functions of medullary MRF which is an intermediate station are also sig-
nificantly affected [4, 17]. In addition, it is clear that the degeneration of the brain stem areas 
that depress the locomotion during REM sleep also causes the complex motor movements 
(increasing in locomotion) of the RBD. As a result, loss of function of these brainstem struc-
tures regulating REM sleep causes the clinic of RBD to occur (Figure 1) [4, 17, 20].
It has been reported that in the first phase of the Braak staging, Lewy body pathology begins 
at the dorsal motor nucleus of the medulla oblongata. In the second stage, pathology pro-
gresses upwards and affects the magnocellular reticular nucleus, sublateral dorsal nucleus, 
and olfactory structures. The PPN is degenerated by Lewy body pathology in the third phase 
of the Braak staging [17]. Thus, RBD in PD is caused by Lewy body pathology involving the 
brain stem structures that play a role in the regulation of REM sleep. It has been reported that 
there are “REM-on” and “REM-off” zones in the brain stem of the rats [25]. On the other hand, 
the relationship between hypocretin and REM sleep remains a controversial issue [26, 27]. 
Parkinson's Disease - Understanding Pathophysiology and Developing Therapeutic Strategies6
A review article reported that hypocretin can stabilize the REM-on and REM-off pontine areas 
in the brain and can also participate in spinal motor neuron inhibition [25]. A study suggested 
that decreased hypocretin levels were associated with RBD due to loss of stabilization in the 
REM regulation of muscle atonia [26].
4.4. Treatment of RBD in PD
Currently, the two most commonly used drugs in the treatment of RBD are melatonin and 
clonazepam. Melatonin is the second choice in the treatment of RBD and is usually an alterna-
tive option in patients with sleep apnea or mental impairment. It is recommended to take mel-
atonin between 3 and 12 mg doses before bedtime [17]. The mechanism of action of melatonin 
Figure 1. Pathophysiology of rapid eye movement (REM) sleep behavior disorder in PD. PD: Parkinson’s disease; PPN/
LDN: pedunculopontine nucleus/laterodorsal tegmental nucleus; PS: pre-coeruleus; SLD: sublaterodorsal nucleus; PRF: 
pontine reticular formation; MRF: medullary magnocellular reticular formation; SIN: spinal interneuron. 1. Direct route; 
2. indirect route inhibiting the spinal motor neurons via the reticular formation. In REM sleep, muscle atonia occurs 
following the activation of the medullary magnocellular and the pontine reticular formations inhibiting the spinal motor 
neurons [4, 19]. There are descending connections from the PPN to the pontine and medullary reticular formations, and 
the spinal cord. There are also descending connections from SLD to the MRF and the spinal motor neurons. Thus, it may 
be considered that inhibition of muscle tone arises both from activating the retikülospinal neurons in both the PRF and 
the MRF of the cholinergic neurons in the PPN and from activating the retikülospinal neurons in the MFR of the neurons 
in the SLD [4, 19].
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in RBD is still unclear. However, melatonin may resolve RBD-related complaints by decreas-
ing muscle tone during REM sleep [28, 29]. Melatonin has many side effects such as daytime 
sleepiness, morning headache, and mental deterioration and is usually associated with high 
doses [17]. Clonazepam is widely used in RBD and doses between 0.25 and 1.0 mg taken 
before bedtime are sufficient for treating the RBD symptoms [17]. Like melatonin, the mecha-
nisms of action of clonazepam in RBD are not fully clear. However, it has been believed 
that clonazepam modulates dreaming/complex motor behaviors at supratentorial levels 
[17]. Clonazepam may worsen symptoms of sleep apnea and mental disorder [30]. It has 
been reported that the most important side effects of clonazepam are sedation, imbalance, 
and sexual dysfunction [17]. If these two treatments are not adequately answered or there 
is a contraindication, rivastigmine, donepezil, pramipexole, and paroxetine may be tried [8]. 
One study showed that rivastimine significantly reduced the frequency of RBD episodes at 
the end of the third week in 12 PD patients with classical treatment-resistant RBD [31]. The 
authors suggest that this effect is related to the peripheral cholinergic action of rivastigmine 
[31]. In a recent review, it has been reported that there are limited evidences indicating that 
drugs such as zopiclone, desipramine, clozapine, carbamazepine, and sodium oxybate may 
be effective in RBD [8].
5. Insomnia
5.1. Clinical features of insomnia
Insomnia is defined as difficulties initiating sleep (initial insomnia), sleep maintenance prob-
lem (i.e., frequent awakenings/sleep fragmentation) or early awakening [2, 6]. In studies, it 
has been reported that the frequency of insomnia in patients with PD varies from 27 to 80% 
[32–35]. It has been reported that the most common types of insomnia in PD patients are sleep 
fragmentation (81%), and early awakenings (terminal insomnia; 40%) [8]. It has been reported 
that insomnia may occur alone or accompany comorbid mental or systemic illnesses, and it is 
associated with disease duration and female gender [6]. Sleep fragmentation is defined as a 
deterioration of sleep integrity (i.e., waking up several times during the night), and it leads to 
a lighter sleep or wakefulness [2]. In studies, it has been reported that sleep fragmentation is 
the most common sleep disorder (74–88%) in patients with PD [36, 37].
5.2. Diagnosis of insomnia in PD
In the diagnosis of insomnia in PD, the clinical history including the stages (defined above) of 
insomnia and its associated factors are essential. For example, the factors associated with ini-
tial insomnia should be learned from the clinical history because the identification of factors 
associated with insomnia is necessary for the treatment plan. Table 2 shows the factors associ-
ated with insomnia [2, 6]. For example, for the diagnosis of RLS, as a reason for the difficulty 
of falling into sleep, clinical assessment (sleep history) is sufficient. Thus, patients should 
be asked for the features in the definition mentioned below for the diagnosis of RLS [6]. In 
contrast to idiopathic RLS, family history of RLS is less frequent in PD [6]. Polysomnography 
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and actigraphy can be used to detect the objective findings of the insomnia [15]. It has been 
reported that insomnia’s PSG findings may be an increase in the number of brief EEG arous-
als—or arousal index, number of stage shifts to stage 1 or wake, wake time after sleep onset 
(WASO), and percentage of stage 1 sleep [2]. The actigraphic findings of insomnia include 
the presence of irregularity in sleep onset and increased number of awakening times during 
the night [15]. One review has been reported that studies comparing PSG to actigraphy in 
insomnia show that PSG and actigraphy have no significant difference in showing the mea-
surements of WASO, total sleep time (TST), and sleep efficacy [38].
5.3. Pathophysiology of insomnia in PD
In the pathogenesis of insomnia in PD, damage of the brain regions associated with sleep has 
an essential role [6]. In addition to PD pathophysiology, motor symptoms of PD, medications, 
mood disorders, pain, physical disability (lack of exercise), and poor sleep hygiene are other 
factors contributing to the pathogenesis of insomnia in PD [6, 8]. Thus, the etiology of insom-
nia in PD is multifactorial, and it can include intrinsic sleep disorders such as altered dream 
phenomena, RBD, restless leg syndrome (RLS), and periodic leg movements in sleep-PLMS), 
PD symptoms such as nocturnal akinesia and rigidity, pain, nocturia, and psychiatric comor-
bidities such as anxiety, and medications (Table 2) [6, 8].
The restless legs syndrome, which is a cause of insomnia (by making sleeping difficult), is 
characterized by an urge to move the legs typically accompanied by tingling, paresthesia, or 
unpleasant sensations in the legs, which is worsened during periods of inactivity and improved 
by voluntary movement [2, 6]. In RLS, symptoms are often worse in the evening or at night 
[2, 6]. It has been reported that the prevelance of RLS in PD varies from 0 to 50% [6]. It has 
been reported that there has a role of central dopaminergic depletion in the pathophysiology 
Factors Initial insomnia Maintenance insomnia
Psychiatric comorbidities Depression and anxiety Depression and anxiety
Intrinsic sleep disorders RLS RBD
Medications Selegiline, amantadine, caffeine, 
SSRI
Excessive dopaminergic therapy
Sleep-related movement 
disorders
RLS, painful leg cramps Periodic leg movements
Pain Back pain Dystonia-related pain
PD symptoms Annoying tremor Nocturnal akinesia/difficulty turning right and 
left in bed
Others Non-motor fluctuations, systemic 
illnesses
Nocturia, systemic illnesses
PD: Parkinson’s disease; RBD: rapid eye movement sleep behavior disorder; SSRI: selective serotonin reuptake inhibitors; 
RLS: restless legs syndrome.
Table 2. Factors associated with insomnia in PD.
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of both RLS and PD [2]. On the other hand, it has been reported that the most common causes 
of wakings during the night are nocturia and difficulty turning right and left in bed [6]. 
Studies have shown that the frequency of sleep fragmentation in PD is related to the clinical 
severity of the disease, as evidenced by the UPDRS and Hoehn and Yahr (HY) scales [39, 40].
5.4. Treatment of insomnia in PD
The first step in the treatment of insomnia must be to determine the type (i.e., initial, of main-
tenance, or terminal) of insomnia and the possible factors affecting it such as medications 
that can cause insomnia [2, 8]. A treatment plan should then be made. For example in initial 
insomnia, behavioral therapies such as photo therapy, sleep hygiene measures, relaxation, 
and cognitive therapy may be recommended first and medications such as hypnotics (e.g., 
Zolpidem, eszopiclone-newer benzodiazepine receptor agonist) or sedating anti-depressants 
(e.g., mirtazapine and trazodone)may be given if necessary [6, 8, 15, 41]. It has been recom-
mended that hypnotics should be avoided in patients with sleep apnea syndrome [15]. In 
initial insomnia, melatonin receptor agonists such as ramelteon may also be helpful [8, 15]. 
Sedating anti-depressants may also be used for maintenance insomnia [8]. However, clonaz-
epam (long-acting sedative) taken at bedtime may be a good option for the treatment of main-
tenance insomnia (i.e., sleep fragmentation) due to PLMS [42]. If insomnia is due to motor 
disability of PD, evening dose of controlled-release levodopa to prevent immobility improves 
insomnia [8]. It has been reported that dopamine agonists may influence the subjective symp-
toms of insomnia [2]. On the other hand, because of central dopaminergic depletion has a 
role in the pathophysiology of both RLS and PD [2], the dopamine agonists (e.g., pramipexole 
and ropinirole) used in idiopathic RLS can also be recommended in the treatment of RLS in 
PD [2, 6]. In addition, since dopamine agonists reduce RLS and PLMS, they may be useful in 
decreasing sleep fragmentation [43]. Although levodopa is effective in RLS, it is not recom-
mended because it causes side effects such as RLS augmentation and morning rebound [44]. 
If there is an additional symptom associated with RLS, such as pain, treatment options may 
be include pregabalin, gabapentin, opiates, and benzodiazepines [45, 46]. In PD, PLMS is less 
common and its frequency increases in the advanced stages of the disease [47].
Atypical antipsychotics are not recommended for the treatment of insomnia without a psy-
chotic disorder [15].
6. Excessive daytime sleepiness
6.1. Clinical features of EDS
Excessive daytime sleepiness is a chronic or episodic sleepiness seen throughout the day in 
PD patients [2]. Anxiety and depression, cognitive dysfunction, changes in sleeping habits, 
changes in circadian rhythm, the side effects of medications that can produce sleep attacks 
such as dopamine agonists, and concomitant systemic diseases can cause sleepiness [2, 48]. 
Also these factors can cause fatigue [2]. Studies have reported that EDS is very common 
in PD. Verbaan et al. [49] found that compared to controls (10%), 43% of PD patients had 
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EDS. One study found that EDS was related to age and male gender [50]. Also, other sleep 
disorders such as PLMS, and sleep fragmentation which cause the deterioration of night sleep 
quality may be the other causes of EDS [6, 15].
6.2. Diagnosis of excessive daytime sleepiness in PD
In patients describing the symptoms of EDS, it is very important to determine the level of 
sleepiness. The Epworth Sleepiness Scale (ESS) is widely used in the evaluation of EDS. Thus, 
ESS (score greater than 10) is a useful scale for the subjective assessment of sleepiness in 
patients with EDS [51].The ESS contains eight items, and each item is rated as maximum three 
points. A higher score means more sleepiness level. In addition, there are objective tests such 
as multiple sleep latency test (MSLT) and maintenance of wakefulness test (MWT) for assess-
ment EDS. The MWT is evaluation used as a polysomnographic measurement of EDS. The 
MSLT is measured after a PSG performed in the night to assess nighttime sleep quality and 
quantity [52]. One study found that the risk (sensitivity 75%) of traffic accidents increased in 
PD patients with an ESS score greater than 7 [53].
6.3. Pathophysiology of excessive daytime sleepiness in PD
It has been reported that there are three main causes of sleepiness in PD; (1) deterioration of 
night sleep quality, (2) neurodegeneration of sleep–wake-related brain regions, as a result of 
disease pathology, and (3) the side effects of antiparkinsonian medications [6, 32]. However, 
many of the abovementioned causes may be related to EDS. For this reason, it is necessary to 
consider these causes in the diagnosis and treatment of EDS.
6.4. Treatment of excessive daytime sleepiness in PD
The first step in the treatment of EDS should be the correction of underlying conditions [8]. For 
example, it may be useful to treat the conditions that disturb sleep quality at night or to arrange 
medications that cause daytime sleep episodes. After that, pharmacological treatment options 
for EDS should be considered. Nonpharmacological treatment approaches (e.g., good sleep 
hygiene, bright light therapy) can be performed in the treatment of mild to moderate EDS cases 
[54]. Modafinil is widely used for the symptomatic treatment of EDS, which appears to stimu-
late catecholamine production [55]. Common side effects of modafinil are insomnia, headache, 
dry mouth, dizziness, nausea, nervousness, and depression [56]. A review has reported that 
sodium oxybate and methylphenidate have inadequate evidence that they are effective in the 
treatment of EDS in PD [8]. Amantadine and selegiline are reported to have an alerting effect 
[2]. Thus, amantadine and selegiline may be preferentially used in PD patients with EDS.
7. Diagnostic assessment of sleep disorders in PD
The history taken from the patient and its neighbors (e.g., partner) is very important in assess-
ing sleep disorders in PD. The type of sleep disorder should be identified in the history, and 
information about possible related factors should be obtained from the history. In PD, general 
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and specific scales can be used to investigate the subtype of sleep disorder and to determine 
its severity. Objective methods can be used to further investigate the diagnosis of these disor-
ders. Further investigative techniques include sleep recording methods such as actigraphy or 
PSG. Polysomnographic findings of each sleep disorder have been explained in the relevant 
section. In addition, information about screening scales used in each sleep disorder has been 
described in the relevant section.
Actigraphy is an electrophysiological device that measures the movements of the patient dur-
ing sleep by recording from wrist or ankle for many days. Actigraphy evaluates indirectly 
the circadian sleep–wake patterns [15]. It is especially used in circadian rhythm disorders or 
insomnia and prolonged daytime sleepiness [15].
8. Deep brain stimulation in the treatment of sleep disorders in PD
Studies investigating the effect of DBS in the treatment of sleep disorders in PD patients 
showed that DBS improved the sleep scales and quality [57–60]. Baumann-Vogel et al. [58] 
found that subthalamic nucleus (STN) DBS-enhanced subjective sleep quality, reduced sleep-
iness measured by the Epworth sleepiness scale, and reduced sleep fragmentation shown 
by actigraphy recordings. However, the authors observed that subthalamic DBS was not 
improved REM sleep features [58]. Similarly, Cicolin et al. [59] reported that RBD symptoms 
did not benefit from STN DBS. On the other hand, Chahine et al. [61] reported that STN DBS 
improved significantly symptoms of RLS in PD patients. The effect of PPN DBS on sleep 
disorders in PD has been investigated in several studies [57, 62]. One study showed that PPN 
DBS improved sleep quality and reduced EDS; however, it caused a reduction in REM latency 
and a relevant increase in REM sleep [57]. In another study, it has been reported that PPN 
DBS improved the total duration and rate of REM sleep [62]. As a result, DBS seems to be 
beneficial in the treatment of sleep disorders in PD because it seems to be useful in improving 
sleep quality. However, large-scale prospective studies are needed to understand the benefits 
of DBS in the treatment of sleep disorders in PD.
9. Conclusion
Sleep disorders in PD are common. In the pathogenesis of sleep disorders in PD, degenera-
tion of the brain regions associated with sleep has an essential role. Sleep disorders in PD can 
impair patients’ quality of life. For this reason, it is very important to recognize and treat sleep 
disorders in PD. The history taken from the patient and its neighbors (e.g., partner) is the first 
step in assessing sleep disorders in PD. Sleep scales and objective assessment methods can 
be used to further investigate sleep disorders. In addition to the type of the sleep disorder, 
its related factors (i.e., comorbidities) in PD should be determined from the sleep history 
of the patient. Symptomatic treatment of sleep disorder and correction of factors associated 
with it should be the next steps. The age of the patient and accompanying diseases should be 
considered when choosing medical drugs used for symptomatic treatment of sleep  disorders. 
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Side effects of some medicines may be fatal in patients with comorbidities. For example, 
clonazepam used RBD may worsen symptoms of sleep apnea and mental disorder [30]. 
Further studies are needed to improve more specific treatments and better understand the 
pathophysiology of sleep disorders in PD.
Author details
Dursun Aygun
Address all correspondence to: daygun@omu.edu.tr
Department of Neurology, Medical School, Ondokuz Mayis University, Samsun, Turkey
References
[1] Brockmann K, Gasser T. Genetics of Parkinson’s disease. In: Jankovic J, Tolosa E, edi-
tors. Parkinson’s Disease and Movement Disorders. Philadelphia; Wolters Kluwer; 2015. 
pp. 65-74.
[2] Claassen DO, Kutscher SJ. Sleep disturbances in Parkinson’s disease patients and man-
agement options. Nature and Science of Sleep. 2011;(3):125-133
[3] Suzuki K, Okuma Y, Uchiyama T, Miyamoto M, Sakakibara R, Shimo Y, Hattori N, 
Kuwabara S, Yamamoto T, Kaji Y, Hirano S, Kadowaki T, Hirata K. Impact of sleeprel-
ated symptoms on clinical motor subtypes and disability in Parkinson's disease: A multi-
centre cross-sectional study. Journal of Neurology, Neurosurgery, and Psychiatry. 2017. 
pii: jnnp-2017-316136
[4] Rodriguez CL, Jaimchariyatam N, Budur K. Rapid eye movement sleep behavior disor-
der: A review of the literature and cpdate on current concepts. Chest. 2017;152:650-662
[5] Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disor-
der in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep 
behaviour disorder. Neurology. 1996;46:388-393
[6] Santamaria J. Sleep and fatigue in PD. In: Jankovic J, Tolosa E, editors. Parkinson’s 
Disease and Movement Disorders. Philadelphia: Wolters Kluwer; 2015. pp. 428-439
[7] Falup-Pecurariu C, Diaconu Ş. Sleep dysfunction in Parkinson's disease. International 
Review of Neurobiology. 2017;133:719-742
[8] Loddo G, Calandra-Buonaura G, Sambati L, Giannini G, Cecere A, Cortelli P, Provini 
F. The treatment of sleep disorders in Parkinson's disease: From research to clinical prac-
tice. Frontiers in Neurology. 2017;8:42
[9] Kim YE, Jeon BS. Clinical implication of REM sleep behavior disorder in Parkinson’s 
disease. Journal of Parkinsons Disease. 2014;4:237-244
Sleep Disorders in Parkinson’s Disease
http://dx.doi.org/10.5772/intechopen.73520
13
[10] Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioral disorders of 
human REM sleep: A new category of parasomnia. Sleep. 1986;9:293-308
[11] American Academy of Sleep Medicine. International Classification of Sleep Disorders. 
3rd ed. Westchester, IL: American Academy of Sleep Medicine; 2014
[12] Zhang J, Xu CY, Liu J. Meta-analysis on the prevalence of REM sleep behavior disorder 
symptoms in Parkinson's disease. BMC Neurology. 2017;17:2
[13] Aygun D, Turkel Y, Onar MK, Sunter T. Clinical REM sleep behavior disorder and motor 
subtypes in Parkinson's disease: A questionnaire-based study. Clinical Neurology and 
Neurosurgery. 2014;119:54-58
[14] Zhu R, Xie C, Hu P, Wang K. Clinical variations in Parkinson’s disease patients with or 
without REM sleep behaviour disorder: A meta-analysis. Scientific Reports. 2017;7:40779
[15] Sudhansu C, Avidan AY. Sleep and its disorders. In: Daroff RB, Jancovic J, Mazziotta JC, 
Pomeroy SL, editors. Bradley’s Neurology in Clinical Practice. Philadelphia: Elsevier; 
2016. pp. 1615-1685
[16] Nomura T, Inoue Y, Kagimura T, Uemura Y, Nakashima K. Utility of the REM sleep 
behavior disorder screening questionnaire (RBDSQ) in Parkinson’s disease patients. 
Sleep Medicine. 2011;12:711-713
[17] St Louis EK, Boeve AR, Boeve BF. REM sleep behavior disorder in Parkinson's disease 
and other synucleinopathies. Movement Disorders. 2017;32:645-658
[18] Rye DB, Jankovic J. Emerging views of dopamine in modulating sleep/wake state from 
an unlikely source: PD. Neurology. 2002;58:341-346
[19] Takakusaki K, Chiba R, Nozu T, Okumura T. Brainstem control of locomotion and mus-
cle tone with special reference to the role of the mesopontine tegmentum and medullary 
reticulospinal systems. Journal of Neural Transmission. 2016;123:695-729
[20] Wang HL, Morales M. Pedunculopontine and laterodorsal tegmental nuclei contain dis-
tinct populations of cholinergic, glutamatergic and GABAergic neurons in the rat. The 
European Journal of Neuroscience. 2009;29:340-358
[21] Takakusaki K, Habaguchi T, Saitoh K, Kohyama J. Changes in the excitability of 
hindlimbmotoneurons during muscular atonia induced by stimulating the pedunculo-
pontine tegmental nucleus in cats. Neuroscience. 2004;124:467-480
[22] Martinez-Gonzalez C, van Andel J, Bolam JP, Mena-Segovia J. Divergent motor projec-
tions from the pedunculopontine nucleus are differentially regulated in parkinsonism. 
Brain Structure and Function 2014;219:1451-1462.
[23] Gut NK, Winn P. The pedunculopontine tegmental nucleus—A functional hypothesis 
from the comparative literature. Movement Disorders. 2016;31:615-624
[24] Chen MC, Yu H, Huang Z-L, Lu J. Rapid eye movement sleep behavior disorder. Current 
Opinion in Neurobiology. 2013;23:793-798
Parkinson's Disease - Understanding Pathophysiology and Developing Therapeutic Strategies14
[25] McCarter SJ, St Louis EK, Boeve BF. REM sleep behavior disorder and REM sleep 
without atonia as an early manifestation of degenerative neurological disease. Current 
Neurology and Neuroscience Reports. 2012;12:182-192
[26] Knudsen S, Gammeltoft S, Jennum PJ. Rapid eye movement sleep behaviour dis-
order in patients with narcolepsy is associated with hypocretin-1 deficiency. Brain. 
2010;133:568-579
[27] Anderson KN, Vincent A, Smith IE, Shneerson JM. Cerebrospinal fluid hypocretin levels 
are normal in idiopathic REM sleep behaviour disorder. European Journal of Neurology. 
2010;17:1105-1107
[28] Kunz D, Mahlberg R. A two-part, double-blind, placebocontrolled trial of exogenous 
melatonin in REM sleep behaviour disorder. Journal of Sleep Research. 2010;19:591-596
[29] McGrane IR, Leung JG, St Louis EK, Boeve BF. Melatonin therapy for REM sleep behav-
ior disorder: A critical review of evidence. Sleep Medicine. 2015;16:19-26
[30] Li SX, Lam SP, Zhang J, et al. A prospective, naturalistic follow-up study of treatment 
outcomes with clonazepam in rapid eye movement sleep behavior disorder. Sleep 
Medicine. 2016;21:114-120
[31] Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine 
as alternative treatment for refractory REM behavior disorder in Parkinson’s disease. 
Movement Disorders. 2012:559-561
[32] Gjerstad MD, Wentzel-Larsen T, Aarsland D, et al. Insomnia in Parkinson’s disease: 
Frequency and progression over time. Journal of Neurology, Neurosurgery, and 
Psychiatry. 2007;78:476-479
[33] Zhu K, van Hilten JJ, Marinus J. The course of insomnia in Parkinson’s disease. 
Parkinsonism & Related Disorders. 2016;33:51-57
[34] Lima M. Sleep disturbances in Parkinson’s disease: The contribution of dopamine in 
REM sleep regulation. Sleep Medicine Reviews. 2013;17:367-375
[35] Adler C, Thorpy M. Sleep issues in Parkinson’s disease. Neurology. 2005;64(Suppl 3): 
S13-S20
[36] Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect 
in Parkinson’s disease. Movement Disorders. 1990;5:280-285
[37] Oerlemans WG, de Weerd AW. The prevalence of sleep disorders in patients with 
Parkinson’s disease: A self-reported, community-based survey. Sleep Medicine. 2002;3: 
147-149
[38] Martin JL, Hakim AD. Wrist actigraphy. Chest. 2011;139:1514-1527
[39] Porter B, Macfarlane R, Walker R. The frequency and nature of sleep disorders in a 
community-based population of patients with Parkinson’s disease. European Journal of 
Neurology. 2008;15:50-54
Sleep Disorders in Parkinson’s Disease
http://dx.doi.org/10.5772/intechopen.73520
15
[40] Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson’s disease. Movement 
Disorders. 2002;17:775-781
[41] Menza M, Dobkin RD, Marin H, Gara M, Bienfait K, Dicke A, Comella CL, Cantor C, 
Hyer L. Treatment of insomnia in Parkinson's disease: A controlled trial of eszopiclone 
and placebo. Movement Disorders. 2010;25:1708-1714
[42] Guilleminault C, Crowe C, Quera-Salva MA, Miles L, Partinen M. Periodic leg move-
ment, sleep fragmentation and central sleep apnoea in two cases: Reduction with clon-
azepam. European Respiratory Journal. 1988;1:762-765
[43] Mehta SH, Morgan JC, Sethi KD. Sleep disorders associated with Parkinson’s disease: 
Role of dopamine, epidemiology, and clinical scales of assessment. CNS Spectrums. 
2008;13(Suppl 4):6-11
[44] Garcia-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminer-
gic augmentation of restless legs syndrome: Report from a world Association of Sleep 
Medicine International Restless Legs Syndrome Study Group consensus conference at 
the Max Planck Institute. Sleep Medicine. 2007;8:520-530
[45] Garcia-Borreguero D, Lar rosa O, de la Llave Y, Verger K, Masramon X, Hernandez 
G. Treatment of restless legs syndrome with gabapentin: A double-blind, cross-over 
study. Neurology. 2002;59:1573-1579
[46] Lesage S, Hening WA. The restless legs syndrome and periodic limb movement disor-
der: A review of management. Seminars in Neurology. 2004;24:249-259
[47] Poewe W, Högl B. Akathisia, restless legs and periodic limb movements in sleep in 
Parkinson's disease. Neurology. 2004;63(Suppl 3):S12-S16
[48] Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and Parkinson's disease 
treatment. Lancet. 2000;355:1333-1334
[49] Verbaan D, van Rooden SM, Visser M, Marinus J, van Hilten JJ. Nighttime sleep prob-
lems and daytime sleepiness in Parkinson's disease. Movement Disorders. 2008;23:35-41
[50] Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Excessive daytime 
sleepiness in Parkinson disease: Is it the drugs or the disease? Neurology. 2006;67:853-858
[51] Johns MW. A new method for measuring daytime sleepiness: The Epworth sleepiness 
scale. Sleep. 1991;14:540-545
[52] Sullivan SS, Kushida CA. Multiple sleep latency test and maintenance of wakefulness 
test. Chest. 2008;134:854-861
[53] Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime 
sleepiness and sudden-onset sleep in Parkinson disease: A survey by the Canadian 
movement disorders group. JAMA. 2002;287:455-463
[54] Knie B, Mitra MT, Logishetty K, Chaudhuri KR. Excessive daytime sleepiness in patients 
with Parkinson's disease. CNS Drugs. 2011;25:203-212
Parkinson's Disease - Understanding Pathophysiology and Developing Therapeutic Strategies16
[55] Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for 
treating subjective daytime sleepiness in patients with Parkinson’s disease. Movement 
Disorders. 2003;18:287-293
[56] Rodrigues TM, Castro Caldas A, Ferreira JJ. Pharmacological interventions for daytime 
sleepiness and sleep disorders in Parkinson’s disease: Systematic review and meta-anal-
ysis. Parkinsonism & Related Disorders. 2016;27:25-34
[57] Peppe A, Pierantozzi M, Baiamonte V, Caltagirone C, Stanzione P, et al. Deep brain stim-
ulation of pedunclopontine tegmental nucleus: Role in sleep modulation in advanced 
Parkinson’s disease patients: One-year follow-up. Sleep. 2012;35:1637-1642
[58] Baumann-Vogel H, Imbach LL, Sürücü O, Stieglitz L, Waldvogel D, Baumann CR, Werth 
E. The impact of subthalamic deep brain stimulation on sleep-wake behavior: A pro-
spective electrophysiological study in 50 Parkinson patients. Sleep. 2017;40(5). DOI: 
10.1093/sleep/zsx033
[59] Cicolin A, Lopiano I, Zibetti M, torre E, Tavella A, Gistamacchia G, et al. Effects of deep 
brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian 
patients. Sleep Medicine. 2004;5:207-210
[60] Amara AW, Standaert DG, Guthrie S, Cutter G, Watts RL, Walker HC. Unilateral sub-
thalamic nucleus deep brain stimulation improves sleep quality in Parkinson's disease. 
Parkinsonism & Related Disorders. 2012;18:63-68
[61] Chahine LM, Ahmed A, Sun Z. Effects of STN DBS for Parkinson’s disease on restless 
legs syndrome and other sleep-related measures. Parkinsonism & Related Disorders. 
2011;17:208-211
[62] Lim AS, Moro E, Lozano AM, et al. Selective enhancement of rapid eye movement sleep 
by deep brain stimulation of the human pons. Annals of Neurology. 2009;66:110-114
Sleep Disorders in Parkinson’s Disease
http://dx.doi.org/10.5772/intechopen.73520
17

